Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi

CiteScore 2018: 2.43

SCImago Journal Rank (SJR) 2018: 0.947
Source Normalized Impact per Paper (SNIP) 2018: 0.837

See all formats and pricing
More options …
Volume 32, Issue 2


Identification and management of familial breast cancer in Austria

Christian F. Singer
  • Corresponding author
  • Department of Obstetrics and Gynecology, Medical University of Vienna, AKH Wien, Waehringer Guertel 18-20, 1090 Vienna, Austria
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Yen Y. Tan
  • Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Christine Rappaport
  • Department of Obstetrics and Gynecology and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2017-11-30 | DOI: https://doi.org/10.1515/hmbci-2017-0025



The aim of this study is to review the legal implications, the technology, the indications and the management of women with a familial background of breast and/or ovarian cancer.


We have reviewed the literature and national Austrian guidelines to describe the uptake of genetic counseling and the management options offered in Austria.


Genetic testing for the BRCA1 and 2 mutations is free and readily available through a nation-wide program. Increased awareness and the availability of screening programs and prophylactic surgery have resulted in a profound increase in genetic counseling and testing in women with a familial background of breast and ovarian cancer in Austria.


While readily available country-wide counseling has led to an increase in counseling and testing, Austrian legislation mandates “non-directional counseling” resulting in a comparatively low uptake of prophylactic surgery.

Keywords: Austria; BRCA1; BRCA2; familial breast cancer; genetic counseling; national guidelines


  • [1]

    Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705–13.PubMedCrossrefGoogle Scholar

  • [2]

    Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet. 1998;62:676–89.CrossrefPubMedGoogle Scholar

  • [3]

    Marsh DJ, Howell VM. The use of denaturing high performance liquid chromatography (DHPLC) for mutation scanning of hereditary cancer genes. Methods Mol Biol. 2010;653:133–45.Web of ScienceCrossrefGoogle Scholar

  • [4]

    Ekstrøm PO, Bjørge T, Dørum A, Longva AS, Heintz KM, Warren DJ, et al. Determination of hereditary mutations in the BRCA1 gene using archived serum samples and capillary electrophoresis. Anal Chem. 2004;76:4406–9.CrossrefPubMedGoogle Scholar

  • [5]

    Wallace AJ. New challenges for BRCA testing: a view from the diagnostic laboratory. Eur J Hum Genet. 2016;24:S10–8.Web of SciencePubMedCrossrefGoogle Scholar

  • [6]

    Kozlowski P, Jasinska AJ, Kwiatkowski DJ. New applications and developments in the use of multiplex ligation-dependent probe amplification. Electrophoresis. 2008;29:4627–36.Web of ScienceCrossrefGoogle Scholar

  • [7]

    Singer CF, Tea MK, Pristauz G, Hubalek M, Rappaport C, Riedl CC, et al. Clinical practice guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families. Wien Klin Wochenschr. 2015;127:981–6.Web of ScienceCrossrefPubMedGoogle Scholar

  • [8]

    George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14:284–96.PubMedWeb of ScienceGoogle Scholar

  • [9]

    Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer. 2012;107:24–30.CrossrefWeb of SciencePubMedGoogle Scholar

  • [10]

    Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.CrossrefPubMedGoogle Scholar

  • [11]

    Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. J Am Med Assoc. 2006;296:185–92.CrossrefGoogle Scholar

  • [12]

    Bermejo-Pérez MJ, Márquez-Calderón S, Llanos-Méndez A. Effectiveness of preventive interventions in BRCA1/2 gene mutation carriers: a systematic review. Int J Cancer. 2007;121:225–31.Web of ScienceCrossrefPubMedGoogle Scholar

  • [13]

    Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, et al. Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol. 2015;1:306–13.PubMedCrossrefWeb of ScienceGoogle Scholar

  • [14]

    Riedl CC, Luft N, Bernhart C, Weber M, Bernathova M, Tea MK, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol. 2015;33:1128–35.PubMedWeb of ScienceCrossrefGoogle Scholar

  • [15]

    Gschwantler-Kaulich D, Schrenk P, Bjelic-Radisic V, Unterrieder K, Leser C, Fink-Retter A, et al. Mesh versus acellular dermal matrix in immediate implant-based breast reconstruction - A prospective randomized trial. Eur J Surg Oncol. 2016;42:665–71.PubMedCrossrefGoogle Scholar

  • [16]

    Singer CF, Muhr D, Rappaport C, Tea MK, Gschwantler-Kaulich D, Fink-Retter A, et al. Clinical implications of genetic testing for BRCA1 and BRCA2 mutations in Austria. Clin Genet. 2014;85:72–5.Web of ScienceCrossrefPubMedGoogle Scholar

  • [17]

    Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van ’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22:1055–62.CrossrefGoogle Scholar

  • [18]

    Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al. Breast cancer risk following oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23:7491–6.CrossrefPubMedGoogle Scholar

About the article

Received: 2017-05-01

Accepted: 2017-08-30

Published Online: 2017-11-30

Author Statement

Research funding: Authors state no funding involved.

Conflict of interest: Authors state no conflict of interest.

Informed consent: Informed consent is not applicable.

Ethical approval: The conducted research is not related to either human or animals use.

Citation Information: Hormone Molecular Biology and Clinical Investigation, Volume 32, Issue 2, 20170025, ISSN (Online) 1868-1891, DOI: https://doi.org/10.1515/hmbci-2017-0025.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Wenhui Li, Lei Li, and Ming Wu
Hereditary Cancer in Clinical Practice, 2019, Volume 17, Number 1

Comments (0)

Please log in or register to comment.
Log in